Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C

Annals of Pharmacotherapy

Volumn 41, Issue 2, 2007, Pages 268-275

  Dar Santos, Anne E ^a   Partovi, Nilufar ^b,c   Ford, Jo Ann E ^d   Yoshida, Eric M ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d British Columbia Hepatitis Program   (United States)

Author keywords

Epoetin; Filgrastim; Hepatitis C

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; INTERFERON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADJUVANT THERAPY; ANEMIA; ARTHRALGIA; BACTERIAL INFECTION; BONE PAIN; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; EMBASE; FATIGUE; GRANULOCYTOSIS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LOW DRUG DOSE; MEDLINE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PARAMETER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; REVIEW; SEIZURE; SPLEEN RUPTURE; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; THROMBOCYTOSIS; TREATMENT DURATION; VOMITING;

ANEMIA; CHEMOTHERAPY, ADJUVANT; EPOETIN ALFA; FILGRASTIM; HEMATINICS; HEPATITIS C; HUMANS; INTERFERONS; MEDLINE; NEUTROPENIA; RIBAVIRIN;

EID: 33847370310     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H169     Document Type: Review

References (46)

1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease. MMWR Morb Mortal Wkly Rep 1998;47(RR-19):1-40.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:555-62.
3. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(suppl 1):S30-4.
4. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24(suppl 2):S3-8.
5. World Health Organization. Hepatitis C fact sheet N°164. www.who.int/mediacentre/factsheets/fs164/en/print/html (version current at September 16, 2005).
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
9. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
10. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
11. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
12. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alfa-2a (40kd)/ribavirin therapy. Hepatology 2006;43:954-60.
13. Stader DB, Wright T, Thomas DL, Seeff LB. AASLD Practice Guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-70.
14. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
15. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
16. Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004;2:337-9.
17. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19(suppl 1):S17-24.
18. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004.
19. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003;37(suppl 4):S315-22.
20. Bruchfeld A, Lindahl K, Schvarcz R, Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002;24:701-8.
21. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hep 2004;11:84-7.
22. Maeda Y, Kiribayashi Y, Moriya T, et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004;26:9-15.
23. Wong S, Kaita K, Gauthier T, et al. A comparative trial of recombinant interferon alpha 2a versus alpha 2b on myelosuppression in healthy adult volunteers. Hepatogastroenterology 1996;43:301-5.
24. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 suppl 1):S237-44.
25. Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1633-9.
26. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003;37:533-41.
27. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9.
28. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
29. Juarez-Navarro A, Vera-de-Leon L, Navarro JM, et al. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon alfa-α2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 2005;27:317-22.
30. Hillman RS. Hematopoietic agents. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of drugs. Toronto: McGraw-Hill, 2001:1311-40.
31. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
32. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37(1suppl):s182-238.
33. Stravitz TR, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005;100:1415-9.
34. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
35. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
36. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
37. Shiffman ML, di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
38. Spiegel BM, Chen K, Chiou CF, et al. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005;3:1034-42.
39. AHFS drug information 2005. Bethesda, MD: American Society of Health-System Pharmacists, 2005:1486-506.
40. Brown SL, Dale DC. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells (letter). Biol Blood Marrow Transplant 1997;3:341-3.
41. Arshad M, Seiter K, Bilaniuk J, et al. Side effects related to cancer treatment: case 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005;23:8533-4.
42. Kuendgen A, Fenk R, Bruns I, et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;38:69-70.
43. Sood A, Reddy N, Russo MW, et al. Use of granulocyte colony stimulating factor (G-CSF) for interferon induced neutropenia in patients with chronic hepatitis C infection (abstract). Hepatology 2001;34:429A.
44. Koliouskas D, Didiropoulos I, Masmanidou M, et al. Comparative analysis and effect of GM-CSF on neutropenia in peg-interferon alpha-2b and ribavirin-treated chronic hepatitis C patients (abstract). Hepatology 2002;36:587A.
45. Carey E, Rosati M, Anderson M, et al. Use of G-CSF allows for optimal PEG-INF dosing during therapy for hepatitis C virus with pegylated interferon and ribavirin (abstract). Hepatology 2002;36:604A.
46. Lebray P, Nalpas B, Vallet-Pichard A, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C. Antivir Ther 2005;10:769-76.